
Based on these results, tirzepatide could be first medication approved for treatment of obstructive sleep apnea in patients with obesity.

Based on these results, tirzepatide could be first medication approved for treatment of obstructive sleep apnea in patients with obesity.

Managing these treatments involves many considerations, including glycemic control and nutrition, among others.

The quadruplet regimen added bortezomib to the current standard of care, which is a triplet regimen of isatuximab, lenalidomide, and dexamethasone for patients with transplant-ineligible, newly diagnosed multiple myeloma (NDMM TI).

Presenters at the American Diabetes Association 84th Scientific Sessions analyzed potential developments in treatment for patients with diabetes and diabetic kidney disease.

There are numerous challenges with cell and gene therapies in oncology, such as accessibility, cost, and prior authorizations, as well as the need for improved education and training within the oncology community.

The study shows that tirzepatide significantly improves secondary outcomes in patients with sleep apnea.

Tim Mok, PharmD, BCOP, BCPS, discusses innovative therapies that are changing the treatment options available for patients with hematologic malignancies.

With improved technology and innovations for diabetes, it is essential for health care providers and health agencies to collaborate to combat rising rates of diabetes.

After being previously approved in June 2023 under an Accelerated Approval process, the FDA has granted an expanded approval for non-ambulatory individuals and individuals 4 years of age or older.

Niki Shah Vice President of Impact Innovation and Activation at McKesson, previews the 2024 McKesson ideaShare conference.

The potential to optimize medication efficacy and safety across diverse populations is garnering attention in various health care settings.

American Diabetes Association Scientific Sessions speaker Ivan de Araujo emphasizes the importance of the pharmacist’s role in diabetes care and his hopes for the future of care.

Treatment focuses on reducing symptoms and preventing further progression.

Fostering communication and shared terminology is key.


Pharmacy Times will be at McKesson ideaShare 2024 Conference in New Orleans, Louisiana from June 23 to June 26, 2024.

Pharmacists Can Help Patients Select Probiotic Products and Advise Them on When to Seek Further Care.

Ryan Haumschild discusses the evolving treatment landscape for patients with multiple myeloma.

Additionally, the high cost of the cell therapy raises concerns for broader access.

Hyperhidrosis affects an estimated 10 million individuals in the US and is characterized by abnormally increased sweating, beyond what is necessary to regulate body temperature.

Ambient-UVB radiation could improve 25(OH)D prediction in the future, improving widespread vitamin D deficiencies among non-White individuals.

Autism spectrum disorder was also evaluated in the analysis, but further research is required to determine a possible association with relative age effect.

Investigators compared the reference products of adalimumab (Humira; AbbVie) and etanercept (Enbrel; Amgen) with biosimilar products.

Pharmacy experts can provide transition interventions tailored to individual patients

Caution Patients Against the Use of Redness-Reducing Eye Drops.

Pharmacy Times will be at the American Diabetes Association (ADA) 84th Scientific Sessions in Orlando, Florida from June 21 to June 24, 2024.

Compared with standard of care chemoimmunotherapy, acalabrutinib with bendamustine and rituximab reduced risk of death or disease by approximately 27%.

Impaired glucose tolerance is a significant risk factor for developing diabetes.

Being able to communicate in a different language can improve treatment adherence and medication efficacy outcomes

Participants in the study had durable response for over 1 year, in addition to positive efficacy indicators.